Dietary therapy formula for repairing gastric mucosa and inhibiting helicobacter pylori and preparation method thereof

Abstract

The invention relates to the field of functional food and natural product chemistry, in particular to a dietary therapy formula for repairing gastric mucosa and inhibiting helicobacter pylori and a preparation method of the dietary therapy formula. According to the formula, astragalus polysaccharide and 3-hydroxy-4-methoxyphenylacetamide which are modified by a glycyrrhizic acid-amino acid deep eutectic system are used as main components, and natural auxiliaries such as Chinese yam extract, lycium barbarum polysaccharide, pericarpium citri reticulatae flavone, maltooligosacharide and honey powder are used as auxiliary components. Hydrogen bond rearrangement and intercalation structure optimization of the astragalus polysaccharide are realized through deep eutectic modification, and the stability and adhesiveness of the astragalus polysaccharide in a gastric acid environment are remarkably improved; the 3-hydroxy-4-methoxyphenylacetamide can specifically inhibit the activity of helicobacter pylori urease and block the adhesion of the helicobacter pylori urease, so that the dual effects of repairing and bacteriostasis are realized. The formula is simple in preparation process and high in safety, and the obtained product is superior to a contrast in the aspects of gastric mucosa repair rate, bacteriostasis rate and acid resistance, and has a good dietary therapy application prospect.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of functional foods and natural product chemistry, and in particular to a food therapy composition for repairing gastric mucosa and inhibiting Helicobacter pylori and a preparation method thereof. BACKGROUND

[0002] Helicobacter pylori is an important pathogenic factor causing chronic gastritis, peptic ulcer and gastric cancer, and about 50% of the population is infected with it. The bacterium can survive in the acidic environment of the stomach and erode the gastric mucosa, leading to damage to the stomach tissue. Currently, the conventional method for treating Helicobacter pylori infection is mainly the combined treatment of antibiotics and proton pump inhibitors. Although this scheme can effectively inhibit the growth of Helicobacter pylori and improve the symptoms of gastric ulcer, long-term use of antibiotics can lead to drug resistance, intestinal flora imbalance and other side effects, while proton pump inhibitors can also cause some damage to the natural environment of the stomach, affecting the normal repair of the gastric mucosa.

[0003] Existing drugs mostly focus on killing bacteria or inhibiting gastric acid secretion, and have limited repair effect on the gastric mucosa. In order to accelerate the repair of the gastric mucosa, some studies have begun to try to use natural plant ingredients, such as Astragalus, ginseng, and wolfberry, to help repair damaged gastric mucosa. However, existing food therapy formulations still have obvious limitations in the dual role of inhibiting Helicobacter pylori and repairing the gastric mucosa. Most of the Chinese medicine ingredients have low bioavailability, or only have a single function, and lack effective synergistic effect.

[0004] Although some studies attempt to achieve the combined effect of gastric mucosa repair and Helicobacter pylori inhibition through plant polysaccharides and natural antibacterial ingredients, the stability and release effect of these ingredients in the gastric acid environment have not yet reached the ideal state. In the prior art, most plant extracts have not been modified, and their antibacterial and adhesive properties are insufficient, resulting in a significant reduction in their effect in the stomach environment.

[0005] Therefore, there is an urgent need for a food therapy composition that can simultaneously repair the gastric mucosa, inhibit Helicobacter pylori, and have good stability. An ideal food therapy composition should utilize the synergistic effect of natural substances to enhance their bioavailability and stability in the gastric acid environment, and have no side effects in long-term use, providing a safe and effective treatment regimen. SUMMARY

[0006] In order to overcome the deficiencies in the background art, the purpose of the present application is to provide a food therapy formula for repairing gastric mucosa and inhibiting Helicobacter pylori and a preparation method thereof. The present application combines modified astragalus polysaccharide by glycyrrhizic acid-amino acid deep eutectic system with 3-hydroxy-4-methoxyphenylacetamide, supplemented with natural ingredients such as yam extract, lycium barbarum polysaccharide and citrus peel flavones, to form a composite food therapy formula through scientific proportioning and reasonable preparation process. Through the synergistic effect of natural plant extracts and modified polysaccharide, the gastric mucosa repair ability is significantly improved and the growth of Helicobacter pylori is effectively inhibited, providing a safe, effective and stable food therapy scheme.

[0007] The purpose of the present application can be achieved by the following technical solutions:

[0008] A food therapy formula for repairing gastric mucosa and inhibiting Helicobacter pylori, comprising the following raw materials by weight: modified astragalus polysaccharide by glycyrrhizic acid-amino acid deep eutectic system 20-40 parts; 3-hydroxy-4-methoxyphenylacetamide 5-15 parts; yam extract 10-20 parts; lycium barbarum polysaccharide 5-15 parts; citrus peel flavones 2-8 parts; malt oligosaccharide 5-10 parts; honey powder 2-5 parts; deionized water 100-150 parts; wherein the modified astragalus polysaccharide by glycyrrhizic acid-amino acid deep eutectic system refers to a deep eutectic solvent constructed by glycyrrhizic acid monosodium salt and L-glutamic acid as a modification medium, which is used to regulate the structure of astragalus polysaccharide through hydrogen bond rearrangement and molecular intercalation, thereby improving its stability and biological adhesion in the gastric acid environment; the 3-hydroxy-4-methoxyphenylacetamide refers to an organic small molecule with a benzene ring-acetamide skeleton structure, which can inhibit the urease activity of Helicobacter pylori and block its adhesion on the surface of gastric epithelial cells, thereby exerting antibacterial and gastric mucosa protection effects.

[0009] Optionally, the modified astragalus polysaccharide by glycyrrhizic acid-amino acid deep eutectic system comprises the following raw materials by weight: astragalus polysaccharide 80-120 parts; glycyrrhizic acid monosodium salt 10-20 parts; L-glutamic acid 20-30 parts; deionized water 200-300 parts.

[0010] Optionally, the preparation method of the modified astragalus polysaccharide by glycyrrhizic acid-amino acid deep eutectic system comprises the following steps:

[0011] (1) Add astragalus polysaccharide to deionized water and stir until completely dissolved to form a uniform solution;

[0012] (2) Add glycyrrhizic acid monosodium salt and L-glutamic acid to the uniform solution and mix thoroughly to form a deep eutectic solvent system;

[0013] (3) After the reaction is completed, cool to room temperature, add anhydrous ethanol for precipitation, filter, centrifuge, and freeze-dry the precipitate to obtain the modified astragalus polysaccharide by glycyrrhizic acid-amino acid deep eutectic system.

[0014] Optionally, the mixing condition of step (2) is temperature 60℃, and reaction time 3 hours.

[0015] Optionally, a preparation method of a food therapy formula for repairing gastric mucosa and inhibiting Helicobacter pylori, comprising the following steps:

[0016] S1, accurately weighing the glycyrrhizin acid-amino acid deep eutectic system modified astragalus polysaccharide, 3-hydroxy-4-methoxy phenylacetamide, yam extract, lycium barbarum polysaccharide, citrus peel flavone, malt oligosaccharide, honey powder and deionized water;

[0017] S2, the solid raw materials such as glycyrrhizin acid-amino acid deep eutectic system modified astragalus polysaccharide, yam extract, lycium barbarum polysaccharide, citrus peel flavone, malt oligosaccharide and honey powder are put into a stirring container, and uniformly mixed to ensure uniform distribution of the solid raw materials;

[0018] S3, a proper amount of deionized water is added to the mixed solid raw materials, and a stirrer is used to fully stir the liquid and solid raw materials, so that all components are completely wetted and uniformly dispersed;

[0019] S4, continue to stir at a proper stirring speed until a uniform slurry is formed, and ensure that all components are fully mixed;

[0020] S5, after completing the stirring, the uniformity of the mixture is checked to ensure that there is no caking or stratification phenomenon, and finally a uniform food therapy formula slurry is obtained.

[0021] Optionally, the operating condition of step S2 is that the stirring speed is 1000-1500 rpm, and the stirring time is 10-15 minutes, so as to ensure uniform distribution of the solid raw materials.

[0022] Optionally, the reaction condition of step S3 is temperature 60℃, and reaction time 3 hours.

[0023] Optionally, the reaction condition of step S4 is that the stirring time is 10-15 minutes, and the stirring process is kept at a uniform speed to ensure the formation of a uniform slurry.

[0024] The beneficial effects of the present application are:

[0025] This invention employs an innovative combination of Astragalus polysaccharide modified with a glycyrrhizic acid-amino acid deep eutectic system and 3-hydroxy-4-methoxyphenylacetamide. This combination results in molecular-level rearrangement and intercalation enhancement of the Astragalus polysaccharide structure, significantly improving its stability and adhesion in an acidic gastric environment, while also endowing the system with excellent antibacterial carrier properties. 3-hydroxy-4-methoxyphenylacetamide, an organic small molecule not previously used in gastric mucosal repair, specifically inhibits the urease pathway of Helicobacter pylori and blocks its adhesion sites. The synergistic effect of these two components achieves a novel dietary therapy mechanism integrating gastric mucosal repair and antibacterial inhibition, thus maintaining high activity and targeted action even in an acidic gastric environment. Attached Figure Description

[0026] The invention will now be further described with reference to the accompanying drawings.

[0027] Figure 1 The infrared spectra of Astragalus polysaccharide and Astragalus polysaccharide modified by the glycyrrhizic acid-amino acid deep eutectic system are compared.

[0028] Figure 2 Comparison of gastric mucosal repair performance test results for samples with different formulation ratios;

[0029] Figure 3 A comparison chart of the test results of Helicobacter pylori inhibition performance of samples with different ratios;

[0030] Figure 4 A comparison chart of gastric acid stability test results for samples with different ratios;

[0031] Figure 5 A comparison chart showing the bioadhesion test results of samples with different ratios. Detailed Implementation

[0032] The present invention will be further described below with reference to specific embodiments. However, the present invention is not limited to the following embodiments. Equivalent adjustments made without departing from the spirit and essence of the present invention should also be considered to fall within the protection scope of the present invention.

[0033] Example 1

[0034] The purpose of this embodiment is to verify the gastric mucosal repair effect and Helicobacter pylori inhibition ability of a combination of modified Astragalus polysaccharide and organic small molecules at a lower ratio under low content conditions, so as to provide a benchmark for the formulation concentration gradient study.

[0035] S1, 80 parts of astragalus polysaccharide were added into 200 parts of deionized water to form a uniform solution by stirring and dissolving; 10 parts of monosodium glycyrrhizinate and 20 parts of L-glutamic acid were added into the solution to form a deep eutectic solvent system; the system was stirred at 60°C for 3 hours to promote the rearrangement of intermolecular hydrogen bonds and intercalation; after the reaction, the system was cooled to room temperature, anhydrous ethanol was added for precipitation, and the precipitate was filtered, centrifuged, and freeze-dried to obtain modified astragalus polysaccharide;

[0036] S2, 20 parts of modified astragalus polysaccharide, 5 parts of 3-hydroxy-4-methoxyphenylacetamide, 10 parts of yam extract, 5 parts of wolfberry polysaccharide, 2 parts of orange peel flavones, 5 parts of malt oligosaccharide, 2 parts of honey powder, and 100 parts of deionized water were accurately weighed; all the solid raw materials were placed in a stirring container and stirred at a speed of 1200 rpm for 12 minutes to uniformly disperse the components;

[0037] S3, deionized water was gradually added to the mixed solid raw materials, and stirring was continued until a uniform slurry was formed; the stirring was maintained at 60°C for 3 hours, and then the uniformity of the mixture was checked, and the stirring was stopped after no clumps or stratification was found;

[0038] The obtained slurry can be directly spray-dried or compressed into tablets.

[0039] Example 2

[0040] The purpose of this example is to balance the effective component ratio by using medium proportion components, to verify the synergistic effect between repairing gastric mucosa and bacteriostasis, and to provide a basis for optimizing the formula.

[0041] S1, 100 parts of astragalus polysaccharide were added into 250 parts of deionized water to form a uniform solution by stirring and dissolving; 15 parts of monosodium glycyrrhizinate and 25 parts of L-glutamic acid were added to form a deep eutectic solvent system; after reaction at 60°C for 3 hours, anhydrous ethanol was added for precipitation separation, and the modified astragalus polysaccharide was obtained after filtration, centrifugation, and freeze-drying; Figure 1 The infrared spectrum comparison chart shows that the astragalus polysaccharide modified by the glycyrrhizic acid-amino acid deep eutectic system has significant changes in multiple key wavebands; the O–H and N–H stretching peaks at 3400 cm⁻¹ are enhanced after modification, indicating that the hydrogen bond network is reconstructed; the newly added C=O stretching peak at 1730 cm⁻¹ and the N–H bending peak at 1560 cm⁻¹ indicate that amidation and amino introduction occur; the appearance of the C–N stretching peak at 1250 cm⁻¹ and the strong C–O peak at 1050 cm⁻¹ verifies the polarity modification effect of the deep eutectic system on the polysaccharide skeleton; the overall peak shape is enhanced and the baseline is smooth, indicating that the structure is more compact and stable, and the effective chemical modification and functional group reconstruction of the polysaccharide are successfully achieved;

[0042] S2, weigh 30 parts of modified Astragalus polysaccharide, 10 parts of 3-hydroxy-4-methoxyphenylacetamide, 15 parts of Dioscorea opposita extract, 10 parts of Lycium barbarum polysaccharide, 5 parts of Citrus reticulata flavonoids, 8 parts of maltodextrin, 3 parts of honey powder and 120 parts of deionized water; put all solid raw materials into a mixing container and stir at 1000 rpm for 10 minutes until the solid raw materials are mixed evenly;

[0043] S3. After adding deionized water to the mixture, stir at a uniform speed for 3 hours and maintain the reaction at 60°C to form a homogeneous slurry with good fluidity. After checking that there is no clumping or layering in the mixture, stop stirring and take a sample to dry to obtain a dietary therapy formula with a medium ratio.

[0044] Example 3

[0045] The purpose of this embodiment is to verify the gastric mucosa repair efficiency and antibacterial performance enhancement effect of modified astragalus polysaccharide and 3-hydroxy-4-methoxyphenylacetamide under high concentration conditions by increasing the content of modified astragalus polysaccharide and 3-hydroxy-4-methoxyphenylacetamide.

[0046] S1. Add 120 parts of Astragalus polysaccharide to 300 parts of deionized water and stir thoroughly to form a homogeneous solution; add 20 parts of monosodium glycyrrhizate and 30 parts of L-glutamic acid and mix to form a deep eutectic system; stir the reaction at 60℃ for 3 hours to promote hydrogen bond rearrangement and molecular intercalation; after the reaction is completed, cool to room temperature, add anhydrous ethanol to precipitate, filter, centrifuge and freeze dry to obtain high-concentration modified Astragalus polysaccharide;

[0047] S2. Accurately weigh 40 parts of modified Astragalus polysaccharide, 15 parts of 3-hydroxy-4-methoxyphenylacetamide, 20 parts of Dioscorea extract, 15 parts of Lycium barbarum polysaccharide, 8 parts of Citrus reticulata flavonoids, 10 parts of maltodextrin, 5 parts of honey powder, and 150 parts of deionized water. Put each component into a mixing container and stir at 1500 rpm for 15 minutes to ensure thorough mixing.

[0048] S3. Slowly add deionized water to the mixture and stir at 60°C for 3 hours to form a high-viscosity slurry. After testing that the slurry has a suitable viscosity and is evenly dispersed, stop stirring. The resulting slurry can be dried at low temperature to make powder or tablets, which are suitable for processing dietary therapy products.

[0049] Comparative Example 1

[0050] The purpose of this comparative study is to verify whether the gastric mucosal repair and antibacterial properties of the dietary therapy formula are weakened when only astragalus polysaccharide is modified with monosodium glycyrrhizate, thereby demonstrating the necessity of deep eutectic double modification.

[0051] S1. Add 100 parts of Astragalus polysaccharide to 250 parts of deionized water and stir to dissolve to form a homogeneous solution; add 15 parts of monosodium glycyrrhizate without adding L-glutamic acid and stir directly to form a single modified system; react at 60℃ for 3 hours and then cool; add anhydrous ethanol to precipitate and separate; filter, centrifuge, and freeze dry to obtain glycyrrhizic acid modified Astragalus polysaccharide.

[0052] S2, weigh out 30 parts of single-modified Astragalus polysaccharide, 10 parts of 3-hydroxy-4-methoxyphenylacetamide, 15 parts of Dioscorea opposita extract, 10 parts of Lycium barbarum polysaccharide, 5 parts of Citrus reticulata flavonoids, 8 parts of maltodextrin, 3 parts of honey powder and 120 parts of deionized water; put all solid raw materials into a mixing container and stir at 1000 rpm for 10 minutes until they are evenly mixed;

[0053] S3 added deionized water to the mixture and stirred at a uniform speed for 3 hours, maintaining the reaction at 60°C to form a slurry; after checking the homogeneity of the mixture, stirring was stopped and the mixture was dried to obtain a single glycyrrhizic acid modified formulation.

[0054] Comparative Example 2

[0055] The purpose of this comparative example is to verify whether the same adhesion and biological stability as the dual-modification system can be maintained under the condition of modifying Astragalus polysaccharide with L-glutamic acid alone, thereby demonstrating the synergistic advantages of the glycyrrhizic acid-amino acid deep eutectic system.

[0056] S1. Add 100 parts of Astragalus polysaccharide to 250 parts of deionized water and stir to dissolve to form a homogeneous solution; add 25 parts of L-glutamic acid without adding monosodium glycyrrhizate to form a single amino acid modified system; react at 60℃ for 3 hours and then cool, add anhydrous ethanol to precipitate, filter, centrifuge, and freeze dry to obtain L-glutamic acid modified Astragalus polysaccharide.

[0057] S2, weigh out 30 parts of single-modified Astragalus polysaccharide, 10 parts of 3-hydroxy-4-methoxyphenylacetamide, 15 parts of Dioscorea opposita extract, 10 parts of Lycium barbarum polysaccharide, 5 parts of Citrus reticulata flavonoids, 8 parts of maltodextrin, 3 parts of honey powder and 120 parts of deionized water; put all solid raw materials into a mixing container and stir at 1000 rpm for 10 minutes until well mixed;

[0058] S3, add deionized water to the mixture, stir continuously for 3 hours, and maintain the temperature at 60℃; after stirring, check the homogeneity of the mixture and dry to obtain a single L-glutamic acid modified formulation.

[0059] Comparative Example 3

[0060] The purpose of this comparative example is to verify whether the formulation still has an effective inhibitory effect on Helicobacter pylori without the addition of 3-hydroxy-4-methoxyphenylacetamide, so as to evaluate the core role of this small molecule in the system.

[0061] S1. Add 100 parts of Astragalus polysaccharide to 250 parts of deionized water and stir to dissolve to form a homogeneous solution; add 15 parts of monosodium glycyrrhizate and 25 parts of L-glutamic acid to form a deep eutectic solvent system; react at 60°C for 3 hours, cool, add anhydrous ethanol to precipitate, filter, centrifuge, freeze dry to obtain modified Astragalus polysaccharide.

[0062] S2, weigh out 30 parts of modified Astragalus polysaccharide, 15 parts of Dioscorea opposita extract, 10 parts of Lycium barbarum polysaccharide, 5 parts of Citrus reticulata flavonoids, 8 parts of maltodextrin, 3 parts of honey powder, and 120 parts of deionized water; do not add 3-hydroxy-4-methoxyphenylacetamide. Add all solid raw materials to a mixing container and stir at 1000 rpm for 10 minutes until well mixed;

[0063] S3, after adding deionized water to the mixture, stir at a uniform speed for 3 hours and maintain the reaction at 60°C to form a slurry; after checking the homogeneity of the mixture, stop stirring and dry to obtain the control group formula without organic small molecules.

[0064] Performance testing

[0065] 1. Gastric mucosal repair performance test

[0066] Samples from Examples 1-3 and Comparative Examples 1-3 were prepared into aqueous solutions of the same concentration, and a mouse gastric mucosal injury model was used for the experiment. After inducing gastric mucosal injury with acetylsalicylic acid, each sample was administered via gavage for 7 consecutive days. After the experiment, gastric tissue was sectioned for observation, and the integrity of the mucosa, glandular arrangement, and inflammatory cell infiltration were analyzed. The results showed that Example 2 exhibited the best gastric mucosal repair effect, with an intact glandular layer structure, uniform blood vessel distribution, and significantly reduced inflammatory response; Examples 1 and 3 also showed significant repair effects. In contrast, Comparative Examples 1 and 2 only formed discontinuous repair layers, with necrotic areas remaining in the tissue; Comparative Example 3 showed a slower repair rate. These results indicate that the synergistic effect of Astragalus polysaccharide modified with a glycyrrhizic acid-amino acid deep eutectic system and small organic molecules can significantly promote gastric mucosal regeneration.

[0067] 2. Helicobacter pylori inhibition performance test

[0068] The inhibitory effect of each sample on Helicobacter pylori was determined using the agar diffusion method. The samples from the examples and comparative examples were prepared into solutions of the same concentration, inoculated into a culture medium containing Helicobacter pylori, and incubated at 37°C for 48 hours. The diameter of the inhibition zone was then measured. The results showed that Example 2 had the largest and most clearly defined inhibition zone, indicating that the composite system had a significant inhibitory effect on Helicobacter pylori. Examples 1 and 3 showed slightly lower inhibition zones but were still significantly better than the comparative examples. Comparative examples 1 and 2, which only contained a single modified system, showed a smaller inhibition zone but continued colony growth. Comparative example 3, which did not contain 3-hydroxy-4-methoxyphenylacetamide, showed a significantly reduced inhibitory ability, indicating the key role of this small molecule in inhibiting the urease activity of Helicobacter pylori.

[0069] 3. Gastric acid stability test

[0070] To evaluate the structural stability of the samples in a gastric acid environment, the example and comparative samples were dissolved in simulated gastric juice at pH 2.0 and treated at a constant temperature of 37°C for 3 hours. Changes in solution viscosity and turbidity were then measured. The results showed that the sample of Example 2 maintained good transparency and viscosity stability under acidic conditions, with almost no precipitation, indicating that the deep eutectic double-modified system significantly enhanced the acid resistance of Astragalus polysaccharides. Examples 1 and 3 performed well but slightly worse than Example 2. Conversely, Comparative Examples 1 and 2 showed significant precipitation and phase separation, indicating severe structural damage. Comparative Example 3, while exhibiting some stability, lacked effective adhesion, verifying the stability advantage of deep eutectic double-modification in an acidic environment.

[0071] 4. Bioadhesion Test

[0072] An in vitro adhesion model was used, with samples dropped onto a biomimetic gastric wall mucin coating to test its adhesion persistence at 37°C. Gastric peristalsis was simulated using a shaking device, and the time required for complete sample detachment was recorded. The results showed that Example 2 exhibited the longest adhesion time, maintaining adhesion on the simulated gastric wall surface for over 60 minutes and forming a uniform mucosal layer. Examples 1 and 3 showed slightly shorter adhesion times but were still significantly better than the comparative examples. Comparative examples 1 and 2, due to insufficient modification, had thin adhesive layers that were easily washed away; Comparative example 3, lacking organic small molecules, showed a significant decrease in adhesion. These results indicate that the molecular synergy between 3-hydroxy-4-methoxyphenylacetamide and modified astragalus polysaccharide plays a crucial role in enhancing gastric wall adhesion.

[0073] Table 1 Summary of performance test results for each sample

[0074] Sample No. Gastric mucosa repair rate (%) Helicobacter pylori inhibition rate (%) Gastric acid stability (residual rate after 3h, %) Adhesion duration (min) Example 1 85.2 88.4 90.6 52 Example 2 95.8 96.3 98.1 63 Example 3 91.4 92.6 94.3 58 Comparative Example 1 73.6 75.2 78.5 40 Comparative Example 2 70.8 72.1 76.9 38 Comparative Example 3 68.5 69.8 81.4 35

[0075] According to the performance data in Table 1, each embodiment showed excellent performance in four indicators: gastric mucosal repair rate, Helicobacter pylori inhibition rate, gastric acid stability, and adhesion duration, and all were significantly better than the comparative embodiment.

[0076] in, Figure 2 Example 2 showed the best overall performance, with a gastric mucosa repair rate of 95.8%. Figure 3 The inhibition rate of Helicobacter pylori in the middle was 96.3%. Figure 4 Even after 3 hours in the acidic environment of the stomach, it still maintained a 98.1% residue rate. Figure 5 The adhesion duration reached up to 63 minutes, demonstrating excellent acid resistance and long-lasting adhesion ability. This indicates a significant synergistic effect between Astragalus polysaccharide modified by the glycyrrhizic acid-amino acid deep eutectic system and 3-hydroxy-4-methoxyphenylacetamide, which can simultaneously enhance gastric mucosal repair and antibacterial properties.

[0077] Although the data for Examples 1 and 3 are slightly lower than those for Example 2, they still maintain a high level, indicating that the system of the present invention has good stability and repeatability under different formulation conditions. Among them, the high-ratio system of Example 3 is slightly better in terms of adhesion and acid resistance, while Example 1 shows a more balanced performance in terms of repair and antibacterial properties, demonstrating the flexibility of formulation.

[0078] In contrast, Comparative Examples 1 and 2, using only a single modified system, showed a decrease in gastric mucosal repair rate to 70%–74%, with significantly weakened antibacterial effect and acid stability. This indicates that single modification is insufficient to form a stable structural network and cannot fully leverage the synergistic effect of modification. In Comparative Example 3, although the modified Astragalus polysaccharide retained some acid resistance after the removal of small organic molecules, both the antibacterial rate and repair rate were significantly reduced, verifying the crucial role of 3-hydroxy-4-methoxyphenylacetamide in inhibiting Helicobacter pylori and promoting gastric wall repair.

[0079] In summary, this invention, through its innovative design of **"deep eutectic dual modification + organic small molecule synergy"**, significantly enhances the structural stability and bioactivity of the polysaccharide system, enabling it to maintain efficient repair and antibacterial functions in a strongly acidic environment, demonstrating clear creative and practical advantages.

Claims

1. A food therapy composition for repairing gastric mucosa and inhibiting Helicobacter pylori, characterized in that, The diet therapy formula contains the following raw materials by weight: 20-40 parts of modified Astragalus polysaccharide by glycyrrhizic acid-amino acid deep eutectic system; 5-15 parts of 3-hydroxy-4-methoxyphenylacetamide; 10-20 parts of Dioscorea extract; 5-15 parts of Lycium barbarum polysaccharide; 2-8 parts of citrus peel flavonoids; 5-10 parts of malt oligosaccharide; 2-5 parts of honey powder; and 100-150 parts of deionized water; wherein the modified Astragalus polysaccharide by glycyrrhizic acid-amino acid deep eutectic system refers to the deep eutectic solvent constructed by glycyrrhizic acid monosodium salt and L-glutamic acid as the modification medium, which is used to regulate the structure of Astragalus polysaccharide through hydrogen bond rearrangement and molecular intercalation, thereby improving its stability and biological adhesion in the gastric acid environment; and the 3-hydroxy-4-methoxyphenylacetamide refers to an organic small molecule with a benzene ring-acetamide skeleton structure, which can inhibit the urease activity of Helicobacter pylori and block its adhesion to the surface of gastric epithelial cells, thereby playing an antibacterial and gastric mucosa protective role.

2. The food therapy composition for repairing gastric mucosa and inhibiting Helicobacter pylori according to claim 1, characterized in that, The modified Astragalus polysaccharide by glycyrrhizic acid-amino acid deep eutectic system contains the following raw materials by weight: 80-120 parts of Astragalus polysaccharide; 10-20 parts of glycyrrhizic acid monosodium salt; and 20-30 parts of L-glutamic acid; and 200-300 parts of deionized water.

3. The food therapy composition for repairing gastric mucosa and inhibiting Helicobacter pylori according to any one of claims 1 or 2, characterized in that, The preparation method of the modified Astragalus polysaccharide by glycyrrhizic acid-amino acid deep eutectic system comprises the following steps: (1) adding Astragalus polysaccharide into deionized water and stirring until completely dissolved to form a uniform solution; (2) adding glycyrrhizic acid monosodium salt and L-glutamic acid into the uniform solution and mixing thoroughly to form a deep eutectic solvent system; (3) after the reaction is completed, cooling to room temperature, adding anhydrous ethanol for precipitation, filtering, centrifuging, and freeze-drying the precipitate to obtain the modified Astragalus polysaccharide by glycyrrhizic acid-amino acid deep eutectic system.

4. The food therapy composition for repairing gastric mucosa and inhibiting Helicobacter pylori according to claim 1, characterized in that, The mixing conditions of step (2) are a temperature of 60°C and a reaction time of 3 hours.

5. A method for preparing a food therapy composition for repairing gastric mucosa and inhibiting Helicobacter pylori, the food therapy composition being as claimed in any one of claims 1 to 4, characterized in that, comprising the following steps: S1, accurately weighing the modified Astragalus polysaccharide by glycyrrhizic acid-amino acid deep eutectic system, 3-hydroxy-4-methoxyphenylacetamide, Dioscorea extract, Lycium barbarum polysaccharide, citrus peel flavonoids, malt oligosaccharide, honey powder, and deionized water; S2, putting the solid raw materials such as the modified Astragalus polysaccharide by glycyrrhizic acid-amino acid deep eutectic system, Dioscorea extract, Lycium barbarum polysaccharide, citrus peel flavonoids, malt oligosaccharide, and honey powder into a stirring container and mixing uniformly; S3, adding an appropriate amount of deionized water into the mixed solid raw materials and using a stirrer to fully stir the liquid and solid raw materials; S4, continuing to stir at an appropriate stirring speed until a uniform slurry is formed; S5, after completing the stirring, checking the uniformity of the mixture to finally obtain a uniform diet therapy formula slurry.

6. The method for preparing a dietary therapy formula for repairing gastric mucosa and inhibiting Helicobacter pylori according to claim 5, characterized in that, The operating conditions of step S2 are a stirring speed of 1000-1500 rpm and a stirring time of 10-15 minutes.

7. The method for preparing a dietary therapy formula for repairing gastric mucosa and inhibiting Helicobacter pylori according to claim 5, characterized in that, The reaction conditions of step S3 are a temperature of 60°C and a reaction time of 3 hours.

8. The method for preparing a dietary therapy formula for repairing gastric mucosa and inhibiting Helicobacter pylori according to claim 5, characterized in that, The reaction conditions of step S4 are a stirring time of 10-15 minutes and maintaining a uniform speed during the stirring process.

Images